Pfizer (NYSE:PFE) Trading 1.6% Higher – What’s Next?

Pfizer Inc. (NYSE:PFE)’s share price traded up 1.6% during trading on Wednesday . The stock traded as high as $25.71 and last traded at $25.5580. 53,627,121 shares changed hands during mid-day trading, an increase of 17% from the average session volume of 45,800,254 shares. The stock had previously closed at $25.15.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported completion of a key China Phase 3 trial for its migraine drug rimegepant, which de-risks global regulatory and commercial rollout in a large market and supports future revenue growth. Pfizer Completes Key China Phase 3 Trial for Migraine Drug Rimegepant
• Positive Sentiment: Pfizer launched a new bioequivalence study for a CGRP migraine asset (early-stage formulation work), signaling continued investment in migraine portfolio expansion and potential lower-cost or differentiated formulations. Pfizer Advances CGRP Migraine Asset With New Bioequivalence Study
• Positive Sentiment: CEO Albert Bourla said Pfizer is pushing for an FDA priority review voucher and is positioning for a large consumer market for obesity drugs (compared to Viagra-era demand), underlining management’s focus on faster regulatory paths and new high-growth categories. These comments support upside expectations if obesity assets and regulatory wins materialize. Pfizer CEO Says Company Is Pushing for FDA Priority Review Voucher
• Positive Sentiment: Management’s obesity strategy (including the $10B Metsera buy) and public guidance about a large consumer opportunity lend optionality to Pfizer’s longer-term growth profile. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: BMO reiterated a Buy and $30 price target, highlighting oncology and obesity pipeline upside and post-loss-of-exclusivity recovery potential—an analyst voice supporting shares. Pfizer: Underappreciated Growth Story Driven by Oncology, Obesity Pipeline, and Post-LOE Recovery Prospects
• Neutral Sentiment: Institutional owners hold ~66% of Pfizer stock, which can stabilize trading but also concentrate influence on strategy and liquidity. Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company
• Neutral Sentiment: Analysts and previews expect steady oncology performance (Seagen ADCs and key brands) that could be offset by pricing and competition—results due with Q4 releases may be a near-term volatility trigger. Inside Pfizer’s Oncology Performance Ahead of Q4 Results
• Negative Sentiment: Investors remain concerned after recent weakness in the stock (market cap decline) tied to conservative 2026 guidance; commentators debate whether downside is a buying opportunity or a sign to stay cautious. Guidance-related uncertainty is pressuring the multiple. PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
• Negative Sentiment: Pfizer stopped a mid-stage lupus skin trial, trimming a potential autoimmune opportunity—a small but negative pipeline read that increases clinical risk mix. Pfizer Ends Mid-Stage Lupus Skin Trial, Trimming a Small but Promising Autoimmune Option
• Negative Sentiment: Critical commentary highlights patent cliff risk, rising debt and the challenge of sustaining buy ratings—items that keep valuation and credit metrics under investor scrutiny. Pfizer’s Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PFE shares. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Morgan Stanley reduced their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. HSBC restated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Finally, Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $27.88.

Pfizer Price Performance

The firm has a market capitalization of $145.32 billion, a P/E ratio of 14.86 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm has a 50 day moving average price of $25.29 and a 200-day moving average price of $24.97.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s payout ratio is currently 100.00%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its stake in Pfizer by 12.9% in the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 25,035 shares of the biopharmaceutical company’s stock worth $607,000 after acquiring an additional 2,858 shares in the last quarter. Goldstone Financial Group LLC raised its stake in shares of Pfizer by 53.8% during the second quarter. Goldstone Financial Group LLC now owns 25,241 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 8,832 shares in the last quarter. Finally, Czech National Bank boosted its holdings in shares of Pfizer by 6.8% in the second quarter. Czech National Bank now owns 1,389,705 shares of the biopharmaceutical company’s stock valued at $33,686,000 after purchasing an additional 88,131 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.